Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Droperidol
Drug ID BADD_D00731
Description A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593)
Indications and Usage Droperidol is used to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.
Marketing Status approved; vet_approved
ATC Code N05AD08
DrugBank ID DB00450
KEGG ID D00308
MeSH ID D004329
PubChem ID 3168
TTD Drug ID D03CJL
NDC Product Code 0143-9515; 64189-0601; 38779-0501; 0143-9514; 0517-9702
UNII O9U0F09D5X
Synonyms Droperidol | Inapsine | Dehidrobenzperidol | Dehydrobenzperidol | Droleptan
Chemical Information
Molecular Formula C22H22FN3O2
CAS Registry Number 548-73-2
SMILES C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation17.02.05.012; 19.06.02.0010.000797%
Akathisia17.01.02.002; 19.06.02.006--
Altered state of consciousness17.02.04.001; 19.07.01.003---
Amenorrhoea05.05.01.002; 21.01.02.001--
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anaphylactic shock10.01.07.002; 24.06.02.004---
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Anxiety19.06.02.002--
Autonomic nervous system imbalance08.01.01.010; 17.05.01.011; 24.06.01.005---
Blood pressure increased13.14.03.005---
Body temperature increased13.15.01.001---
Bronchospasm10.01.03.012; 22.03.01.004--
Cardiac arrest02.03.04.001--
Cardio-respiratory arrest02.03.04.002; 22.02.06.0070.000131%-
Chills08.01.09.001; 15.05.03.016--
Delayed recovery from anaesthesia12.02.20.005; 17.02.04.011---
Depression19.15.01.001--
Dermatitis23.03.04.002---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drug hypersensitivity10.01.01.0010.002417%-
Dysphoria19.04.02.004---
Dyspnoea02.11.05.003; 22.02.01.0040.000196%
Dystonia17.01.03.0010.000287%-
Electrocardiogram QT prolonged13.14.05.004--
Extrapyramidal disorder17.01.02.007--
Galactorrhoea05.03.04.002; 21.05.02.002---
Gynaecomastia05.05.02.003; 21.05.04.003--
Hallucination19.10.04.003--
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperprolactinaemia05.03.01.002---
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene